

CITATION REPORT

List of articles citing

Effects of sildenafil citrate on human hemodynamics

DOI: 10.1016/s0002-9149(99)00043-0

American Journal of Cardiology, 1999, 83, 13C-20C.

Source: <https://exaly.com/paper-pdf/30566180/citation-report.pdf>

Version: 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
297	Sildenafil citrate and blood-pressure-lowering drugs: results of drug interaction studies with an organic nitrate and a calcium antagonist. <i>American Journal of Cardiology</i> , 1999 , 83, 21C-28C	3	222
296	Overall cardiovascular profile of sildenafil citrate. <i>American Journal of Cardiology</i> , 1999 , 83, 35C-44C	3	244
295	Medical treatment of erectile dysfunction. 1999 , 31, 388-98		24
294	Viagra and Cardiovascular Disease. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 1999 , 4, 259-267	2.6	12
293	Literature update: A critical review. 1999 , 14, 405-412		1
292	The use of sildenafil in heart disease. 2000 , 61, 526-7		3
291	Safety of sildenafil. 2000 , 10, 613-5		2
290	Sexual intercourse and stable angina pectoris. <i>American Journal of Cardiology</i> , 2000 , 86, 35F-37F	3	26
289	Cardiovascular risk and sildenafil. <i>American Journal of Cardiology</i> , 2000 , 86, 57F-61F	3	65
288	Effect of sildenafil on coronary active and reactive hyperemia. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2000 , 279, H2319-25	5.2	21
287	Sympathetic activation by sildenafil. <i>Circulation</i> , 2000 , 102, 3068-73	16.7	101
286	Hemodynamic effects of sildenafil in men with severe coronary artery disease. 2000 , 342, 1622-6		257
285	Treatment of dyslipidemia: room for improvement?. 2000 , 20, 2333-5		9
284	Cyclic nucleotide phosphodiesterase type 5 activity limits blood flow to hypoperfused myocardium during exercise. <i>Circulation</i> , 2000 , 102, 2997-3002	16.7	49
283	Sex and the patient with cardiovascular risk factors: focus on sildenafil. 2000 , 109 Suppl 9A, 13S-21S; discussion 29S-30S		32
282	Sildenafil: clinical toxicology profile. 2000 , 38, 645-51		35
281	Relaxation induced by cGMP phosphodiesterase inhibitors sildenafil and zaprinast in human vessels. 2000 , 70, 1327-31		33

280	Sildenafil citrate potentiates the hypotensive effects of nitric oxide donor drugs in male patients with stable angina. <i>Journal of the American College of Cardiology</i> , 2000 , 36, 25-31	15.1	146
279	Acute type 5 phosphodiesterase inhibition with sildenafil enhances flow-mediated vasodilation in patients with chronic heart failure. <i>Journal of the American College of Cardiology</i> , 2000 , 36, 845-51	15.1	250
278	A risk-benefit assessment of sildenafil in the treatment of erectile dysfunction. 2001 , 24, 255-65		3
277	Effect of sildenafil citrate (Viagra) on the ocular circulation. 2001 , 131, 751-5		126
276	Sildenafil citrate: a therapeutic update. <i>Clinical Therapeutics</i> , 2001 , 23, 2-23	3.5	65
275	Acute aortic dissection after cocaine and sildenafil abuse. 2001 , 21, 78-9		19
274	Interactions of sildenafil and tacrolimus in men with erectile dysfunction after kidney transplantation. 2001 , 58, 589-93		14
273	Oral drug therapy for erectile dysfunction. 2001 , 28, 321-34		71
272	Sildenafil Citrate. 2001 , 339-376		12
271	Potential of sildenafil-induced hypotension is minimal with nitrates generating a radical intermediate. 2001 , 38, 149-55		13
270	The cardiovascular response to sexual activity: do we know enough?. 2001 , 24, 271-5		13
269	Evaluation of side effects of sildenafil in group of young healthy volunteers. <i>International Urology and Nephrology</i> , 2001 , 32, 705-8	2.3	12
268	Assessment of the efficacy and safety of Viagra (sildenafil citrate) in men with erectile dysfunction during long-term treatment. 2001 , 13, 261-7		54
267	Effect of sildenafil on blood pressure and arterial wave reflection in treated hypertensive men. 2001 , 15, 707-13		77
266	Transforming growth factor-beta1 inhibits macrophage cholesteryl ester accumulation induced by native and oxidized VLDL remnants. 2001 , 21, 2011-8		70
265	Cardiac electrophysiologic and hemodynamic effects of sildenafil, a PDE5 inhibitor, in anesthetized dogs. 2001 , 38, 940-6		30
264	Ventricular arrhythmia vulnerability in cardiomyopathic mice with homozygous mutant Myosin-binding protein C gene. <i>Circulation</i> , 2001 , 104, 2734-9	16.7	41
263	Effect of inhaled iloprost plus oral sildenafil in patients with primary pulmonary hypertension. <i>Circulation</i> , 2001 , 104, 1218-22	16.7	345

262	Sildenafil inhibits hypoxia-induced pulmonary hypertension. <i>Circulation</i> , 2001 , 104, 424-8	16.7	406
261	Impact of atrial fibrillation on the clinical course of hypertrophic cardiomyopathy. <i>Circulation</i> , 2001 , 104, 2517-24	16.7	571
260	Cardiac phosphodiesterase 5 (cGMP-specific) modulates beta-adrenergic signaling in vivo and is down-regulated in heart failure. 2001 , 15, 1718-26		204
259	Effect of sildenafil on ocular haemodynamics. 2001 , 15, 507-10		40
258	Interaction of sildenafil with cAMP-mediated vasodilation in vivo. <i>Hypertension</i> , 2002 , 40, 763-7	8.5	24
257	Long-term treatment with sildenafil in a thalassemic patient with pulmonary hypertension. 2002 , 100, 1516-7		53
256	Effect of sildenafil on renin secretion in human subjects. 2002 , 227, 620-5		13
255	Sildenafil-nitric oxide donor combination promotes ventricular tachyarrhythmias in the swine right ventricle. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2002 , 282, H1787-92	5.2	9
254	Effect of sildenafil citrate (Viagra) on retinal blood vessel diameter. 2002 , 133, 809-12		54
253	Oral sildenafil is an effective and specific pulmonary vasodilator in patients with pulmonary arterial hypertension: comparison with inhaled nitric oxide. <i>Circulation</i> , 2002 , 105, 2398-403	16.7	508
252	The effect of sildenafil on human vascular function, platelet activation, and myocardial ischemia. <i>Journal of the American College of Cardiology</i> , 2002 , 40, 1232-40	15.1	238
251	Effects of sildenafil citrate (viagra) on blood pressure in normotensive and hypertensive men. 2002 , 59, 747-52		58
250	Phosphodiesterase type 5 as a pharmacologic target in erectile dysfunction. 2002 , 60, 4-11		117
249	A 4-year update on the safety of sildenafil citrate (Viagra). 2002 , 60, 67-90		188
248	Coronary and systemic hemodynamic effects of sildenafil citrate: from basic science to clinical studies in patients with cardiovascular disease. <i>International Journal of Cardiology</i> , 2002 , 86, 131-41	3.2	64
247	Effect of sildenafil on the acute pulmonary vasodilator response to inhaled nitric oxide in adults with primary pulmonary hypertension. <i>American Journal of Cardiology</i> , 2002 , 90, 677-80	3	135
246	[Cardio-vascular effects of sildenafil: new data]. 2002 , 51, 341-5		3
245	Viagra (sildenafil citrate) and ophthalmology. 2002 , 21, 485-506		104

244	Pharmacokinetics of sildenafil after single oral doses in healthy male subjects: absolute bioavailability, food effects and dose proportionality. <i>British Journal of Clinical Pharmacology</i> , 2002 , 53 Suppl 1, 5S-12S	3.8	245
243	Clinical update on sildenafil citrate. <i>British Journal of Clinical Pharmacology</i> , 2002 , 53, 219-23	3.8	10
242	The effect of sildenafil on electrostimulation-induced erection in the rat model. 2002 , 14, 251-5		11
241	The phosphodiesterase 5 inhibitor sildenafil has no effect on cerebral blood flow or blood velocity, but nevertheless induces headache in healthy subjects. 2002 , 22, 1124-31		99
240	Potential for use of pulse wave analysis in determining the interaction between sildenafil and glyceryl trinitrate. 2002 , 25, 295-9		19
239	Molecular mechanisms and pharmacokinetics of phosphodiesterase-5 antagonists. 2003 , 4, 457-65		69
238	Sildenafil: a 4-year update in the treatment of 20 million erectile dysfunction patients. 2003 , 4, 488-96		31
237	Intravenous sildenafil and inhaled nitric oxide: a randomised trial in infants after cardiac surgery. 2003 , 29, 1996-2003		157
236	Effects of sildenafil citrate (Viagra) on hemodynamic parameters during exercise testing and occurrence of ventricular arrhythmias in patients with erectile dysfunction and cardiovascular disease. 2003 , 43, 544-51		12
235	Sildenafil in patients with cardiovascular disease. <i>American Journal of Cardiology</i> , 2003 , 92, 26M-36M	3	32
234	Coronary artery flow reserve in diabetics with erectile dysfunction using sildenafil. 2003 , 2, 8		5
233	Sildenafil does not improve nitric oxide-mediated endothelium-dependent vascular responses in smokers. <i>British Journal of Clinical Pharmacology</i> , 2004 , 57, 209-12	3.8	24
232	Effects of sildenafil on cardiopulmonary responses during stress. 2003 , 169, 1417-21		6
231	Immediate and long-term hemodynamic and clinical effects of sildenafil in patients with pulmonary arterial hypertension receiving vasodilator therapy. 2003 , 78, 1207-13		91
230	Should the patient with coronary artery disease use sildenafil?. 2003 , 6, 161-5		11
229	Sildenafil in erectile dysfunction: a critical review. 2003 , 19, 241-62		77
228	Hemodynamic effects of sildenafil in patients with stable ischemic heart disease. <i>International Journal of Cardiology</i> , 2003 , 90, 153-7	3.2	13
227	Intravenous sildenafil is a potent pulmonary vasodilator in children with congenital heart disease. <i>Circulation</i> , 2003 , 108 Suppl 1, I1167-73	16.7	85

226	Phosphodiesterase type 5 as a target for the treatment of hypoxia-induced pulmonary hypertension. <i>Circulation</i> , 2003 , 107, 3230-5	16.7	205
225	Migraine can be induced by sildenafil without changes in middle cerebral artery diameter. 2003 , 126, 241-7		231
224	Sildenafil citrate does not affect cardiac contractility in human or dog heart. 2003 , 19, 747-52		59
223	Locus for atrial fibrillation maps to chromosome 6q14-16. <i>Circulation</i> , 2003 , 107, 2880-3	16.7	197
222	PDE5 inhibitor sildenafil citrate augments endothelium-dependent vasodilation in smokers. <i>Hypertension</i> , 2003 , 41, 1106-10	8.5	63
221	Effects of sildenafil (viagra) on human myocardial contractility, in vitro arrhythmias, and tension of internal mammaria arteries and saphenous veins. 2003 , 41, 734-43		42
220	Erectile dysfunctions. 2003 , 2, 350-6		2
219	Sildenafil for pulmonary arterial hypertension: exciting, but protection required. <i>Chest</i> , 2003 , 123, 989-93	3.3	24
218	Persistent pulmonary hypertension of the newborn. 2004 , 65, 418-21		
217	Electrophysiological findings in adolescents with atrial fibrillation who have structurally normal hearts. <i>Circulation</i> , 2004 , 110, 117-23	16.7	45
216	Pilot assessment of the response of several pulmonary hemodynamic variables to sublingual sildenafil in candidates for heart transplantation. 2004 , 6, 615-7		35
215	Plasma levels of cAMP, cGMP and CGRP in sildenafil-induced headache. <i>Cephalalgia</i> , 2004 , 24, 547-53	6.1	20
214	Systemic and splanchnic haemodynamic effects of sildenafil in an in vivo animal model of cirrhosis support for a risk in cirrhotic patients. 2004 , 24, 63-8		30
213	Sildenafil citrate does not alter ventricular repolarization properties: novel evidence from dynamic QT analysis. 2004 , 9, 228-33		5
212	Haemodynamic effects of the selective phosphodiesterase 5 inhibitor, UK-357,903, in conscious SHR. <i>British Journal of Pharmacology</i> , 2004 , 141, 114-22	8.6	5
211	Efficacy and safety of sildenafil citrate in men with erectile dysfunction and stable coronary artery disease. <i>American Journal of Cardiology</i> , 2004 , 93, 147-53	3	80
210	Effects of a phosphodiesterase-5 (PDE5) inhibitor on endothelium-dependent relaxation of myometrial small arteries. 2004 , 190, 1283-90		51
209	Erectile dysfunction and cardiovascular disease. 2004 , 79, 782-94		14

208	Interaction between the phosphodiesterase 5 inhibitor, tadalafil and 2 alpha-blockers, doxazosin and tamsulosin in healthy normotensive men. 2004 , 172, 1935-40		133
207	New treatment options for erectile dysfunction in patients with diabetes mellitus. 2004 , 64, 2667-88		69
206	The discovery and development of Viagra® (sildenafil citrate). 2004 , 1-13		4
205	Sildenafil: emerging cardiovascular indications. 2004 , 78, 1496-506		53
204	Cardiovascular effects of the 3 phosphodiesterase-5 inhibitors approved for the treatment of erectile dysfunction. <i>Circulation</i> , 2004 , 110, 3149-55	16.7	143
203	Cardiovascular parameter changes in patients with erectile dysfunction using pde-5 inhibitors: a study with sildenafil and vardenafil. 2004 , 25, 625-9		42
202	Hemodynamic response to sildenafil, nitric oxide, and iloprost in primary pulmonary hypertension. <i>Chest</i> , 2004 , 125, 580-6	5.3	100
201	Acute effects of sildenafil in patients with primary pulmonary hypertension receiving epoprostenol. 2004 , 30, 135-45		18
200	Erectile Dysfunction and Cardiovascular Disease. 2004 , 79, 782-794		49
199	Autonomic control of the cardiovascular system during acclimatization to high altitude: effects of sildenafil. <i>Journal of Applied Physiology</i> , 2004 , 97, 935-40	3.7	57
198	Autonomic dysreflexia during sperm retrieval in spinal cord injury: influence of lesion level and sildenafil citrate. <i>Journal of Applied Physiology</i> , 2005 , 99, 53-8	3.7	74
197	Improved flap viability with site-specific delivery of sildenafil citrate using fibrin glue. 2005 , 55, 292-6		37
196	Opportunity for intervention to achieve American Heart Association guidelines for optimal lipid levels in high-risk women in a managed care setting. <i>Circulation</i> , 2005 , 111, 488-93	16.7	86
195	An oral yohimbine/L-arginine combination (NMI 861) for the treatment of male erectile dysfunction: a pharmacokinetic, pharmacodynamic and interaction study with intravenous nitroglycerine in healthy male subjects. <i>British Journal of Clinical Pharmacology</i> , 2005 , 59, 85-93	3.8	23
194	A case of erectile dysfunction and risk factors for coronary artery disease. 2005 , 17 Suppl 1, S7-S11		3
193	The effects of sildenafil on ocular blood flow. 2005 , 83, 355-9		34
192	Efficacy and safety of sildenafil citrate in men with erectile dysfunction and chronic heart failure. <i>American Journal of Cardiology</i> , 2005 , 95, 36-42	3	51
191	Sexual dysfunction and cardiac risk (the Second Princeton Consensus Conference). <i>American Journal of Cardiology</i> , 2005 , 96, 313-21	3	216

190	Hemodynamic and exercise effects of phosphodiesterase 5 inhibitors. <i>American Journal of Cardiology</i> , 2005 , 96, 32M-36M	3	17
189	Cardiac safety in clinical trials of phosphodiesterase 5 inhibitors. <i>American Journal of Cardiology</i> , 2005 , 96, 37M-41M	3	36
188	Pharmacology and drug interaction effects of the phosphodiesterase 5 inhibitors: focus on alpha-blocker interactions. <i>American Journal of Cardiology</i> , 2005 , 96, 42M-46M	3	63
187	Sexual dysfunction and cardiac risk (the Second Princeton Consensus Conference). <i>American Journal of Cardiology</i> , 2005 , 96, 85M-93M	3	99
186	The therapeutic dilemma: how to use short-acting PDE5 inhibitor drugs. 2005 , 28 Suppl 2, 69-73		2
185	Phosphodiesterase 5 inhibitors and nonarteritic anterior ischemic optic neuropathy (NAION): coincidence or causality?. 2005 , 2, 751-8		15
184	Hemodynamic effects of sildenafil citrate and isosorbide mononitrate in men with coronary artery disease and erectile dysfunction. 2005 , 2, 407-14		15
183	Hemodynamic effects of sildenafil citrate (Viagra) on segmental branches of bilateral renal arteries. <i>International Urology and Nephrology</i> , 2005 , 37, 785-9	2.3	2
182	Efficacy, safety and tolerability of sildenafil in Brazilian hypertensive patients on multiple antihypertensive drugs. 2005 , 31, 342-53; discussion 354-5		10
181	Inhibition of cGMP-specific phosphodiesterase type 5 reduces sodium excretion and arterial blood pressure in patients with NaCl retention and ascites. 2005 , 288, F1044-52		22
180	Sildenafil inhibits beta-adrenergic-stimulated cardiac contractility in humans. <i>Circulation</i> , 2005 , 112, 2642-7	10.7	142
179	In vivo dilation of fetal and neonatal ductus arteriosus by inhibition of phosphodiesterase-5 in rats. 2005 , 58, 42-5		13
178	Effects of sildenafil on the human response to acute hypoxia and exercise. 2005 , 6, 43-9		50
177	Sildenafil: efficacy, safety, tolerability and mechanism of action in treating erectile dysfunction. 2005 , 1, 283-93		34
176	Hipertensi3n arterial, medicaci3n antihipertensiva y disfunci3n er3ctil: una perspectiva basada en la evidencia. 2005 , 3, 13-30		5
175	Phosphodiesterase-5 inhibition: the molecular biology of erectile function and dysfunction. 2005 , 32, 419-29, vi		34
174	Effects of combined treatment with sildenafil and itraconazole on the cardiovascular system in telemetered conscious dogs. 2005 , 28, 177-86		3
173	Safety and efficacy of Sildenafil therapy in children with pulmonary hypertension. <i>International Journal of Cardiology</i> , 2005 , 100, 267-73	3.2	129

172	Effect of Viagra on the foveolar choroidal circulation of AMD patients. <i>Experimental Eye Research</i> , 2005 , 81, 159-64	3.7	33
171	A flexible integration and visualisation system for biomarker discovery. 2006 , 5, 219-23		4
170	Hypertension and Erectile Dysfunction. 2006 , 13, 7-11		
169	Treatment of pulmonary arterial hypertension with sildenafil: from pathophysiology to clinical evidence. <i>Journal of Cardiothoracic and Vascular Anesthesia</i> , 2006 , 20, 722-35	2.1	22
168	Effects of sildenafil citrate (Viagra) on renal arteries: an evaluation with Doppler ultrasound. 2006 , 77, 170-2		4
167	The effects of tamsulosin and sildenafil in separate and combined regimens on detailed hemodynamics in patients with benign prostatic enlargement. 2006 , 176, 2551-6		14
166	Resolution of protein-losing enteropathy and normalization of mesenteric Doppler flow with sildenafil after Fontan. 2006 , 82, e39-40		86
165	Phosphodiesterase-5 inhibitors and omental and placental small artery function in normal pregnancy and pre-eclampsia. 2006 , 127, 41-9		30
164	Effect of regular phosphodiesterase type 5 inhibition in hypertension. <i>Hypertension</i> , 2006 , 48, 622-7	8.5	80
163	Phosphodiesterase type 5 inhibitor sildenafil citrate does not potentiate the vasodilative properties of nebivolol in rat aorta. 2006 , 78, 1103-7		6
162	Cardiovascular safety of sildenafil citrate (Viagra): an updated perspective. 2006 , 68, 47-60		55
161	Effect of sildenafil citrate on postprandial gallbladder motility. 2006 , 99, 208-11		2
160	Sildenafil-associated coronary thrombosis in a patient with angiographically normal coronary arteries: a case report with review of literature. 2006 , 13, 378-84		3
159	Pulmonary hemodynamic responses to brain natriuretic peptide and sildenafil in patients with pulmonary arterial hypertension. <i>Chest</i> , 2006 , 129, 417-425	5.3	79
158	Sildenafil improves cardiac output and exercise performance during acute hypoxia, but not normoxia. <i>Journal of Applied Physiology</i> , 2006 , 100, 2031-40	3.7	104
157	Effects of sildenafil on pulmonary hypertension and exercise tolerance in severe cystic fibrosis-related lung disease. 2006 , 41, 383-5		18
156	Effects of sildenafil citrate on defibrillation efficacy. 2006 , 17, 292-5		14
155	Effect of vardenafil, an inhibitor of phosphodiesterase-5, on portal haemodynamics in normal and cirrhotic liver -- results of a pilot study. 2006 , 23, 121-8		50

154	The proconvulsant effect of sildenafil in mice: role of nitric oxide-cGMP pathway. <i>British Journal of Pharmacology</i> , 2006 , 147, 935-43	8.6	71
153	Sildenafil decreased pulmonary arterial pressure but may have exacerbated portal hypertension in a patient with cirrhosis and portopulmonary hypertension. 2006 , 41, 593-7		31
152	Relaxant effect of sildenafil in the rabbit basilar artery. 2006 , 44, 10-6		11
151	Effect of oral sildenafil citrate on intraoperative hemodynamics in patients with pulmonary hypertension undergoing valvular heart surgery. 2006 , 132, 1420-5		31
150	Influence of intravenous sildenafil on cerebral oxygenation measured by near-infrared spectroscopy in infants after cardiac surgery. 2006 , 59, 462-5		32
149	Effect of intravenous sildenafil on pulmonary hemodynamics and gas exchange in the presence and absence of acute lung injury in piglets. 2006 , 59, 762-6		13
148	Phosphodiesterase type 5 inhibition does not reverse endothelial dysfunction in patients with coronary heart disease. 2006 , 92, 170-6		27
147	The effects of chronic phosphodiesterase-5 inhibitor use on different organ systems. 2007 , 19, 139-48		45
146	Erectile dysfunction and hypertension. 2007 , 19, 296-302		67
145	The effects of sildenafil on heart rate variability in healthy subjects. 2007 , 50, 598-600		4
144	Effects of vardenafil on intraocular pressure and orbital hemodynamics. 2007 , 23, 275-9		4
143	The erectile-endothelial dysfunction nexus: new opportunities for cardiovascular risk prevention. 2007 , 4, 263-73		44
142	Acute effects of a single dose of phosphodiesterase type 5 inhibitor (sildenafil) on systemic arterial blood pressure during exercise and 24-hour ambulatory blood pressure monitoring in heart transplant recipients. 2007 , 39, 3142-9		12
141	Sildenafil and vardenafil but not nitroglycerin limit myocardial infarction through opening of mitochondrial K(ATP) channels when administered at reperfusion following ischemia in rabbits. 2007 , 42, 453-8		105
140	Cyclic guanosine monophosphate phosphodiesterase-5 inhibitor promotes an endothelium NO-dependent-like vasodilation in patients with refractory hypertension. 2007 , 16, 315-21		11
139	Role of oral sildenafil in severe pulmonary arterial hypertension: clinical efficacy and dose response relationship. <i>International Journal of Cardiology</i> , 2007 , 120, 306-13	3.2	52
138	Phosphodiesterase type 5 is highly expressed in the hypertrophied human right ventricle, and acute inhibition of phosphodiesterase type 5 improves contractility. <i>Circulation</i> , 2007 , 116, 238-48	16.7	420
137	Sildenafil citrate ingestion and prolonged priapism and tachycardia in a pediatric patient. 2007 , 45, 798-800		20

136	Sildenafil citrate improves erectile function and urinary symptoms in men with erectile dysfunction and lower urinary tract symptoms associated with benign prostatic hyperplasia: a randomized, double-blind trial. 2007 , 177, 1071-7		282
135	Type 5 phosphodiesterase inhibition in heart failure: the next step. <i>Journal of the American College of Cardiology</i> , 2007 , 50, 2145-7	15.1	14
134	Do vardenafil and tadalafil have advantages over sildenafil in the treatment of erectile dysfunction?. 2007 , 19, 281-95		33
133	Helping the failing heart and penis. 2007 , 61, 716-8		
132	Daily administration of phosphodiesterase type 5 inhibitors for urological and nonurological indications. 2007 , 52, 990-1005		45
131	Acute haemodynamic responses to inhaled nitric oxide and intravenous sildenafil in distal chronic thromboembolic pulmonary hypertension (CTEPH). 2007 , 46, 449-55		28
130	Phosphodiesterase type V: a novel therapeutic target for hypertension. <i>Current Hypertension Reports</i> , 2007 , 9, 119-20	4.7	
129	Phosphodiesterase 5 inhibition in essential hypertension. <i>Current Hypertension Reports</i> , 2008 , 10, 52-7	4.7	27
128	Influence of sildenafil on lung diffusion during exposure to acute hypoxia at rest and during exercise in healthy humans. <i>European Journal of Applied Physiology</i> , 2008 , 103, 421-30	3.4	29
127	Yohimbine enhances the effect of sildenafil on erectile process in rats. 2008 , 20, 409-17		11
126	Failure is an option: learning from unsuccessful proof-of-concept trials. 2008 , 13, 913-6		26
125	An open-label, multicenter, flexible dose study to evaluate the efficacy and safety of Viagra (sildenafil citrate) in Korean men with erectile dysfunction and arterial hypertension who are taking antihypertensive agents. 2008 , 5, 2405-13		5
124	Control of pulmonary vascular tone during exercise in health and pulmonary hypertension. 2008 , 119, 242-63		37
123	Does sildenafil cause myocardial infarction or sudden cardiac death?. 2008 , 8, 1-7		18
122	The use of phosphodiesterase 5 inhibitors with concomitant medications. 2008 , 31, 799-808		49
121	Immediate- and late-hemodynamic coronary effects of tadalafil in men with erectile dysfunction and coronary artery disease. 2008 , 20, 168-72		1
120	Synergy between natriuretic peptides and phosphodiesterase 5 inhibitors ameliorates pulmonary arterial hypertension. 2008 , 178, 861-9		54
119	Sildenafil acts on the central nervous system increasing sympathetic activity. <i>Journal of Applied Physiology</i> , 2008 , 104, 1683-9	3.7	25

118	Sexual dysfunction: the prima ballerina of hypertension-related quality-of-life complications. 2008 , 26, 2074-84		91
117	Phosphodiesterase type 5 inhibition reverses impaired forearm exercise-induced vasodilatation in hypertensive patients. 2008 , 26, 501-7		19
116	Role of phosphodiesterase 5 in synaptic plasticity and memory. 2008 , 4, 371-87		68
115	[Treatment of pulmonary hypertension associated with connective tissue disease]. 2008 , 31, 424-31		1
114	Erectile dysfunction, cardiovascular diseases and depression: interaction of therapy. 2009 , 10, 2107-17		6
113	Influence of alcohol on the hemodynamic effects and pharmacokinetic properties of mirodenafil: a single-dose, randomized-sequence, open-label, crossover study in healthy male volunteers in Korea. <i>Clinical Therapeutics</i> , 2009 , 31, 1234-43	3.5	20
112	The interaction of sildenafil with the anticonvulsant effect of diazepam. <i>European Journal of Pharmacology</i> , 2009 , 617, 79-83	5.3	16
111	Pivotal effects of phosphodiesterase inhibitors on myocyte contractility and viability in normal and ischemic hearts. 2009 , 30, 1-24		45
110	The effect of sildenafil citrate (Viagra) on cerebral blood flow in patients with cerebrovascular risk factors. 2010 , 121, 370-6		18
109	Acute hemodynamic effects of intravenous sildenafil citrate in congestive heart failure: comparison of phosphodiesterase type-3 and -5 inhibition. 2009 , 28, 676-82		40
108	Acute hemodynamic effects of single-dose sildenafil when added to established bosentan therapy in patients with pulmonary arterial hypertension: results of the COMPASS-1 study. 2009 , 49, 1343-52		48
107	2. Phosphodiesterase-5 Inhibitors.. 2010 , 99, 1557-1562		
106	Administration of a low dose of sildenafil for 1 week decreases intrahepatic resistance in rats with biliary cirrhosis: the role of NO bioavailability. 2010 , 119, 45-55		25
105	Postoperative use of oral sildenafil in pediatric patients with congenital heart disease. 2010 , 31, 515-20		18
104	Cardiovascular aspects of sexual medicine. 2010 , 7, 1608-26		80
103	Effect of sildenafil on neuropathic pain and hemodynamics in rats. 2010 , 51, 82-7		16
102	Update on the clinical utility of sildenafil in the treatment of pulmonary arterial hypertension. 2010 , 4, 61-70		28
101	Effects of sildenafil and tadalafil on intraocular pressure in sheep: implications for aqueous humor dynamics. 2010 , 51, 3139-44		26

100	Drug interactions with phosphodiesterase-5 inhibitors used for the treatment of erectile dysfunction or pulmonary hypertension. <i>Circulation</i> , 2010 , 122, 88-95	16.7	78
99	Pharmacokinetic and hemodynamic responses to oral sildenafil during invasive testing in children with pulmonary hypertension. <i>Journal of the American College of Cardiology</i> , 2010 , 55, 1456-62	15.1	25
98	The effect of sildenafil citrate administration on selected physiological parameters of exercising Thoroughbred horses. 2010 , 42, 606-12		6
97	Effect of sildenafil citrate on intraocular pressure and blood pressure in human volunteers. <i>Experimental Eye Research</i> , 2011 , 93, 103-7	3.7	23
96	Phosphodiesterase-5 is a therapeutic target for peripheral neuropathy in diabetic mice. <i>Neuroscience</i> , 2011 , 193, 399-410	3.9	69
95	Phosphodiesterase-5 inhibition mimics intermittent reoxygenation and improves cardioprotection in the hypoxic myocardium. <i>PLoS ONE</i> , 2011 , 6, e27910	3.7	20
94	Safety, tolerability and pharmacokinetics of an intravenous bolus of sildenafil in patients with pulmonary arterial hypertension. <i>British Journal of Clinical Pharmacology</i> , 2011 , 71, 289-92	3.8	50
93	Evidence of diminished coronary flow in pulmonary hypertension: explaining angina pectoris in this patient group?. <i>Clinical Physiology and Functional Imaging</i> , 2011 , 31, 477-84	2.4	1
92	New perspectives for the treatment of pulmonary hypertension. <i>British Journal of Pharmacology</i> , 2011 , 163, 125-40	8.6	47
91	Focus on phosphodiesterase inhibitors for the treatment of erectile dysfunction in older men. <i>Clinical Therapeutics</i> , 2011 , 33, 1590-608	3.5	10
90	Changes in arterial blood flow of free flaps after the administration of sildenafil in swine. <i>Microsurgery</i> , 2011 , 31, 465-71	2.1	11
89	Cardiac uses of phosphodiesterase-5 inhibitors. <i>Journal of the American College of Cardiology</i> , 2012 , 59, 9-15	15.1	65
88	Assessment of the effect of mirodenafil on the hemodynamics of healthy male Korean volunteers administered tamsulosin: a randomized, double-blind, placebo-controlled, 2-period crossover study. <i>Clinical Therapeutics</i> , 2012 , 34, 1929-39	3.5	7
87	Sildenafil accelerates anterior chamber refilling after paracentesis in sheep and rabbits. 2012 , 53, 565-73		9
86	Effects of extracorporeal shock-wave lithotripsy directed at the parotid gland on oxidative stress parameters and some trace element levels in facial nerve of rats. <i>Muscle and Nerve</i> , 2012 , 45, 562-6	3.4	3
85	Antihypertensive treatment and sexual dysfunction. <i>Current Hypertension Reports</i> , 2012 , 14, 285-92	4.7	65
84	Prospective, open-label, uncontrolled pilot study to study safety and efficacy of sildenafil in systemic sclerosis-related pulmonary artery hypertension and cutaneous vascular complications. <i>Rheumatology International</i> , 2013 , 33, 1047-52	3.6	13
83	Acute cardiac and hemodynamic effects of sildenafil on resistant hypertension. <i>European Journal of Clinical Pharmacology</i> , 2013 , 69, 2027-36	2.8	11

82	Sildenafil stimulates aqueous humor turnover in rabbits. <i>Experimental Eye Research</i> , 2013 , 111, 67-70	3.7	8
81	Review: Potential druggable targets for the treatment of early onset preeclampsia. <i>Pregnancy Hypertension</i> , 2013 , 3, 203-10	2.6	5
80	Acute effect of sildenafil on central hemodynamics in mechanically ventilated patients with WHO group III pulmonary hypertension and right ventricular failure necessitating administration of dobutamine. <i>International Journal of Cardiology</i> , 2013 , 167, 848-54	3.2	6
79	Sildenafil exposure and hemodynamic effect after stage II single-ventricle surgery. <i>Pediatric Critical Care Medicine</i> , 2013 , 14, 593-600	3	17
78	Acute effects of sildenafil and dobutamine in the hypertrophic and failing right heart in vivo. <i>Pulmonary Circulation</i> , 2013 , 3, 599-610	2.7	6
77	A standalone perfusion platform for drug testing and target validation in micro-vessel networks. <i>Biomicrofluidics</i> , 2013 , 7, 44125	3.2	28
76	Sildenafil increases sympathetically mediated vascular tone in humans. <i>American Journal of Hypertension</i> , 2013 , 26, 762-9	2.3	12
75	Sildenafil exposure and hemodynamic effect after Fontan surgery. <i>Pediatric Critical Care Medicine</i> , 2014 , 15, 28-34	3	33
74	Improvement of exercise performance and ventilatory efficiency in patients with chronic heart failure after sildenafil use for 8weeks. <i>The Egyptian Journal of Chest Diseases and Tuberculosis</i> , 2014 , 63, 477-481	0.1	
73	Sildenafil vaginal suppositories: preparation, characterization, in vitro and in vivo evaluation. <i>Drug Development and Industrial Pharmacy</i> , 2014 , 40, 803-12	3.6	14
72	Phosphodiesterase 5 Inhibitor Use in Men With Hypertrophic Cardiomyopathy. <i>American Journal of Cardiology</i> , 2015 , 116, 618-21	3	3
71	Impaired neuronal nitric oxide synthase-mediated vasodilator responses to mental stress in essential hypertension. <i>Hypertension</i> , 2015 , 65, 903-9	8.5	13
70	Chloroquine-induced scratching is mediated by NO/cGMP pathway in mice. <i>Pharmacology Biochemistry and Behavior</i> , 2015 , 134, 79-84	3.9	23
69	Phosphodiesterase type 5 inhibitors and kidney disease. <i>International Urology and Nephrology</i> , 2015 , 47, 1521-8	2.3	25
68	A Case Report of Fatal Desmethyl Carbodenafil Toxicity. <i>Journal of Analytical Toxicology</i> , 2017 , 41, 250-255		15
67	Approach to Erectile Dysfunction in Patients with Hypertension and Coronary Artery Disease. 2016 , 309-327		1
66	Can sildenafil improve physical performance at altitude? Current scientific evidence. <i>Apunts Medicine De L'Esport</i> , 2016 , 51, 27-35	0.6	
65	Valsalva Maneuver in Pulmonary Arterial Hypertension: Susceptibility to Syncope and Autonomic Dysfunction. <i>Chest</i> , 2016 , 149, 1252-60	5.3	12

64	Swimming-Induced Pulmonary Edema: Pathophysiology and Risk Reduction With Sildenafil. <i>Circulation</i> , 2016 , 133, 988-96	16.7	44
63	A Phase I proof-of-concept and safety trial of sildenafil to treat cerebral vasospasm following subarachnoid hemorrhage. <i>Journal of Neurosurgery</i> , 2016 , 124, 318-27	3.2	12
62	Sildenafil and retinopathy of prematurity risk in very low birth weight infants. <i>Journal of Perinatology</i> , 2016 , 36, 137-40	3.1	16
61	Treatment of Persistent Pulmonary Hypertension of the Newborn: Use of Pulmonary Vasodilators in Term Neonates. <i>Neonatal Network: NN</i> , 2017 , 36, 160-168	0.8	3
60	Anticonvulsant activity of <i>Pseudospondias microcarpa</i> (A. Rich) Engl. hydroethanolic leaf extract in mice: The role of excitatory/inhibitory neurotransmission and nitric oxide pathway. <i>Journal of Ethnopharmacology</i> , 2017 , 206, 78-91	5	9
59	Potential of the NO-cGMP pathway and blood flow responses during dynamic exercise in healthy humans. <i>European Journal of Applied Physiology</i> , 2017 , 117, 237-246	3.4	4
58	Proof of Principle for a Novel Class of Antihypertensives That Target the Oxidative Activation of PKG I[[Protein Kinase G I]] <i>Hypertension</i> , 2017 , 70, 577-586	8.5	12
57	Cūr et sexe, quoi de neuf?. <i>Sexologies</i> , 2018 , 27, 47-52	0.5	
56	Intersection of Pulmonary Hypertension and Right Ventricular Dysfunction in Patients on Left Ventricular Assist Device Support: Is There a Role for Pulmonary Vasodilators?. <i>Circulation: Heart Failure</i> , 2018 , 11, e004255	7.6	17
55	Evaluation of Pharmacokinetic and Pharmacodynamic Drug-Drug Interaction of Sacubitril/Valsartan (LCZ696) and Sildenafil in Patients With Mild-to-Moderate Hypertension. <i>Clinical Pharmacology and Therapeutics</i> , 2018 , 103, 468-476	6.1	2
54	A New Perspective on the Nitrate-Phosphodiesterase Type 5 Inhibitor Interaction. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2018 , 23, 375-386	2.6	9
53	Sildenafil and calcitonin gene-related peptide dilate intradural arteries: A 3T MR angiography study in healthy volunteers. <i>Cephalalgia</i> , 2019 , 39, 264-273	6.1	9
52	Sildenafil for Pulmonary Hypertension in the Early Postoperative Period After Mitral Valve Surgery. <i>Journal of Cardiothoracic and Vascular Anesthesia</i> , 2019 , 33, 1648-1656	2.1	5
51	Ultra-high field MR angiography in human migraine models: a 3.0 T/7.0 T comparison study. <i>Journal of Headache and Pain</i> , 2019 , 20, 48	8.8	2
50	Sildenafil enhances central hemodynamic responses to exercise, but not V o, in people with diabetes mellitus. <i>Journal of Applied Physiology</i> , 2019 , 127, 1-10	3.7	1
49	Sildenafil does not reliably improve exercise performance in hypoxia: a systematic review. <i>BMJ Open Sport and Exercise Medicine</i> , 2019 , 5, e000526	3.4	2
48	Cysteine-Based Redox Sensing and Its Role in Signaling by Cyclic Nucleotide-Dependent Kinases in the Cardiovascular System. <i>Annual Review of Physiology</i> , 2019 , 81, 63-87	23.1	12
47	The Serendipitous Story of Sildenafil: An Unexpected Oral Therapy for Erectile Dysfunction. <i>Sexual Medicine Reviews</i> , 2019 , 7, 115-128	5.6	53

46	Established and emerging therapeutic uses of PDE type 5 inhibitors in cardiovascular disease. <i>British Journal of Pharmacology</i> , 2020 , 177, 5467-5488	8.6	34
45	Prenatal Use of Sildenafil in Fetal Growth Restriction and Its Effect on Neonatal Tissue Oxygenation-A Retrospective Analysis of Hemodynamic Data From Participants of the Dutch STRIDER Trial. <i>Frontiers in Pediatrics</i> , 2020 , 8, 595693	3.4	0
44	Letter by Opotowsky et al Regarding Article, "Results of the FUEL Trial". <i>Circulation</i> , 2020 , 142, e38-e39	16.7	1
43	Combined Intravenous Sildenafil and L-Arginine Administration in a Porcine Animal Model: Hemodynamic Safety Profile and Effects on Coronary Blood Flow. <i>Drugs in R and D</i> , 2020 , 20, 279-290	3.4	
42	Myeloid-Derived Suppressor Cells as Target of Phosphodiesterase-5 Inhibitors in Host-Directed Therapeutics for Tuberculosis. <i>Frontiers in Immunology</i> , 2020 , 11, 451	8.4	11
41	PDE5 inhibition improves cardiac morphology and function in SHR by reducing NHE1 activity: Repurposing Sildenafil for the treatment of hypertensive cardiac hypertrophy. <i>European Journal of Pharmacology</i> , 2021 , 891, 173724	5.3	2
40	Intradural artery dilation during experimentally induced migraine attacks. <i>Pain</i> , 2021 , 162, 176-183	8	5
39	Sildenafil 4.0-Integrated Synthetic Chemistry, Formulation and Analytical Strategies Effecting Immense Therapeutic and Societal Impact in the Fourth Industrial Era. <i>Pharmaceuticals</i> , 2021 , 14,	5.2	5
38	Nitric Oxide-cGMP Pathway Modulation in an Experimental Model of Hypoxic Pulmonary Hypertension. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2021 , 26, 665-676	2.6	3
37	Sildenafil administration improves right ventricular function on 4D flow MRI in young adults born premature. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2021 , 320, H2295-H2304	5.2	1
36	The Potential Role of Sildenafil in Cancer Management through EPR Augmentation. <i>Journal of Personalized Medicine</i> , 2021 , 11,	3.6	5
35	The Solid State Landscape of the Sildenafil Drug. <i>Journal of Pharmaceutical Sciences</i> , 2021 ,	3.9	0
34	Potential Cardiac Applications of Phosphodiesterase Type-5 Inhibition. 2004 , 207-237		1
33	Phosphodiesterase-5 Inhibition. 2004 , 117-130		1
32	Cardiovascular Safety of Phosphodiesterase-5 Inhibitors. 2004 , 139-161		1
31	Transient renal effects of sildenafil in male kidney transplant recipients. <i>Transplantation</i> , 2001 , 72, 1331-38		10
30	Therapeutic Potential of Phosphodiesterase Inhibitors for Endothelial Dysfunction- Related Diseases. <i>Current Pharmaceutical Design</i> , 2020 , 26, 3633-3651	3.3	3
29	Effect of acute lithium administration on penile erection: involvement of nitric oxide system. <i>International Journal of Reproductive BioMedicine</i> , 2016 , 14, 109-116	1.3	2

28	Sildenafil Citrate Does Not Reprogram Risk of Hypertension and Chronic Kidney Disease in Offspring of Preeclamptic Pregnancies in the Dahl SS/Jr Rat.. <i>Kidney360</i> , 2020 , 1, 510-520	1.8	2
27	Vasorelaxant Effect of Sildenafil on Aorta and Pulmonary Artery in Rabbits. <i>International Journal of Pharmacology</i> , 2005 , 2, 55-59	0.7	1
26	Comparison of Tadalafil and Sildenafil in Controlling Neonatal Persistent Pulmonary Hypertension. <i>Iranian Journal of Pediatrics</i> , 2016 , In Press,	1	3
25	Herzkrankheiten und Sexualit�t – Gef�rdung des kranken Herzens durch Sexualit�t oder Gef�rdung der Sexualit�t durch das kranke Herz. 2001 , 177-184		
24	Therapie. 2002 , 129-246		
23	Sildenafil citrate: a 5-year update on the worldwide treatment of 20 million men with erectile dysfunction. 2004 , 35-47		
22	Safety and Hemodynamic Effects of Sildenafil in Patients With Coronary Artery Disease. 2004 , 179-194		
21	Cardiovascular Safety of Sexual Activity and Phosphodiesterase Type 5 Inhibition. 2004 , 159-181		
20	Cardiovascular safety of sildenafil in the treatment of erectile dysfunction. 2004 , 151-162		
19	The Hemodynamics of Phosphodiesterase-PDE5 Inhibitors. 2004 , 131-137		
18	Sildenafil Citrate and the Nitric Oxide/Cyclic Guanosine Monophosphate Signaling Pathway. 2004 , 89-116		
17	Molecular processing of sildenafil in endothelial function: potential applications in cardiovascular diseases. 2004 , 129-142		
16	Sildenafil, pharmacology of a highly selective PDE5 inhibitor. 2004 , 15-33		2
15	Vasorelaxant Effects of Sildenafil and Verapamil on Isolated Rat Aorta with and without Intact Endothelium. <i>International Journal of Pharmacology</i> , 2005 , 2, 142-145	0.7	1
14	Reinventing the Wheel. 2006 ,		
13	Anesthetic Management in a Patient with Severe Primary Pulmonary Hypertension with Right Ventricular Dysfunction - A case report -. <i>Daehan Macwilgwa Haghoeji</i> , 2008 , 54, 473		
12	Erectile Dysfunction. 2009 , 519-526		
11	Phosphodiesterase Inhibitors in the Treatment of Pulmonary Hypertension. 2011 , 1477-1485		

10	Effects of PDE type 5 inhibitors on left ventricular diastolic dysfunction in resistant hypertension. <i>Arquivos Brasileiros De Cardiologia</i> , 2015 , 104, 85-9	1.2	2
9	Viagra and broken hearts. <i>Canadian Family Physician</i> , 2000 , 46, 257-9, 267-9	0.9	1
8	Pharmacotherapy of sexual dysfunctions : current status. <i>Indian Journal of Psychiatry</i> , 2004 , 46, 213-20	2.2	5
7	Effect of acute lithium administration on penile erection: involvement of nitric oxide system. <i>International Journal of Reproductive BioMedicine</i> , 2016 , 14, 109-16	1.3	0
6	Data_Sheet_1.docx. 2020 ,		
5	Combination of Sildenafil and Ba at a Low Concentration Show a Significant Synergistic Inhibition of Inward Rectifier Potassium Current Resulting in Action Potential Prolongation.. <i>Frontiers in Pharmacology</i> , 2022 , 13, 829952	5.6	0
4	The Role of Sildenafil in Treating Brain Injuries in Adults and Neonates. <i>Frontiers in Cellular Neuroscience</i> , 2022 , 16,	6.1	2
3	Alterations in endothelial nitric oxide synthase activity and their relevance to blood pressure. 2022 , 205, 115256		0
2	Nitric oxide/cGMP/CREB pathway and amyloid-beta crosstalk: From physiology to Alzheimer disease. 2022 ,		5
1	Rare fatal effect of combined use of sildenafil and alcohol leading to Cerebrovascular Accident. 2023 , 95, 102504		0